A Phase 3 Open-Label Randomized Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

Brief description of study

The purpose of this study involves research and is being conducted to determine the safety and efficacy of the investigational agent, rAd-IFN, when given with Celecoxib and Gemcitabine. The sponsor believes that rAd-IFN in combination with Celecoxib and Gemcitabine may help inhibit your tumor growth.

Clinical Study Identifier: s17-01785

ClinicalTrials.gov Identifier: NCT03710876

Principal Investigator: Daniel H. Sterman.

Other Investigators: Vamsidhar Velcheti, Harvey I Pass, Samaan Rafeq, Elaine Shum, Gaetane C. Michaud, Jonathan Gross, Abraham Chachoua, Joshua K Sabari, Jamie L. Bessich, Anissa Lajean Walker, William H. Moore, David Mendoza, Bedros Taslakian, Natalia Cherkassky, Melissa L Martinez, Virginia M Ferreira.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies